CK0804 - Cellenkos, Incyte
INCB57643 - Incyte
Iclusig (ponatinib) - Takeda, Otsuka, Incyte
Zynyz (retifanlimab-dlwr) - Incyte
Jakafi (ruxolitinib) - Novartis, Incyte
Monjuvi (tafasitamab-cxix) - MorphoSys, Xencor, Incyte, Specialised Therap
zilurgisertib (INCB00928) - Incyte
parsaclisib (INCB50465) - Incyte
https://www.businesswire.com/news/home/20230525005514/en/Data-from-Across-Incyte%E2%80%99s-Oncology-Portfolio-Accepted-for-Presentation-at-the-2023-ASCO-Annual-Meeting-and-EHA2023-Hybrid-Congress
 
May 25, 2023
 
Prev Next